Early termination of pivotal trials in Alzheimer's disease—Preserving optimal value for participants and science

Participants in Alzheimer's disease late‐phase clinical trials are frequently confronted with a situation of early termination. We discuss measures to protect the perceived value of study participation and to maximize the scientific value under such circumstances. A communication strategy shoul...

Descripción completa

Detalles Bibliográficos
Autores principales: Gietl, Anton F., Frisoni, Giovanni B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Perspectives
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9790521/
https://www.ncbi.nlm.nih.gov/pubmed/35220681
http://dx.doi.org/10.1002/alz.12605

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9790521/
https://www.ncbi.nlm.nih.gov/pubmed/35220681
http://dx.doi.org/10.1002/alz.12605

Ejemplares similares